FINA BIOSOLUTIONS LLC
Recombinantly expressed atoxic tetanus toxin (M8TT) produced in engineered E. coli for use as a conjugate vaccine carrier protein.
- Sector
- Biotech
- Headquarters
- Rockville, MD
- Latest Form D
- $3M, Nov 2024
- Total capital
- $4M
- Federal grants
- $876K
- 3 awards · 2020–2023
- Rank in peer group#110 of 392
- Private capital raised
- $3M
- 1 Form D · last Nov 2024
- 23 months since last filing
- Federal contracts
- $83K
- 4 awards · Health and Human S, Defense
- Rank in Biotech#336 of 4373
- Granted patents
- 7
- 13 pending · first 2016
- Rank in peer group#17 of 392
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$3M
- Federal grantHealth and Human S · Phase I · E. coli platform for expression of low-cost malaria fusion proteins$298K
- Federal grantHealth and Human S · Phase I · Genetically detoxified tetanus toxin for use in vaccines$289K
- Federal grantHealth and Human S · Phase I · Genetically detoxified tetanus toxin for use in vaccines$289K
- Federal contractHealth and Human S · CRM197 Carrier Protein, Quote # 1169$6K
- Federal contractDefense · Igf::ct::igf$52K
- Federal contractHealth and Human S · Monoclonal Antibodies$10K
Show 1 earlier federal award
- Federal contractHealth and Human S · "other Functions" Igf::ot::igf Coli Fermentation Project$15K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
147months
from FINA BIOSOLUTIONS LLC’s first federal award to its first private round.
- First federal award · Aug 2012
- Health and Human S · $15K
- First Form D · Nov 2024
- $3M · 1st Form D
- Awards before first raise
- 7 awards
An association in public records, not a cause or a prediction.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#110 · top 28%
- Granted patents#17 · top 4%
- Linked publications#1 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Andrew LeesResearcherExecutive Officer, DirectorLinked by 3 patents · $876K in grants as PI
What it has protected
USPTO · 7 granted of 20- GrantedProduction of Soluble Recombinant Proteins without N-Terminal Methionine in E-ColiUSPTOUS 12,104,161
- PendingProduction of Soluble Recombinant ProteinUSPTOApplication 17797851
- PendingChemical Reagents for the Activation of Polysaccharides in the Preparation of Conjugate VaccinesUSPTOApplication 17963436
Show all 20 patent records
- Production of Soluble Recombinant Proteins without N-Terminal Methionine in E-ColiOct 1, 2024 · US 12,104,161Granted
- Production of Soluble Recombinant ProteinAug 3, 2023 · Application 17797851Pending
- Chemical Reagents for the Activation of Polysaccharides in the Preparation of Conjugate VaccinesApr 20, 2023 · Application 17963436Pending
- Production of Soluble Recombinant Protein without N-Terminal MethionineJul 13, 2021 · US 11,060,123Granted
- Expression And Purification Of Crm Proteins And Related Proteins, And Protein DomainsMar 24, 2020 · US 10,597,664Granted
- Expression and Purification of CRM197 and Related ProteinsOct 9, 2018 · US 10,093,704Granted
- Activation Of Polysaccharides Via The Cyanylating Agent, 1-CYANOBENZOTRIAZOLE (1-CBT), In The Preparation Of Polysaccharide/protein Conjugate VaccinesFeb 16, 2016 · US 9,259,480Granted
- Activation of Polysaccharides via the Cyanylating Agent, 2-Cyanopyridazine-3(2H)-One (2-CPO), in the Preparation of Polysaccharide/Protein Conjugate VaccinesFeb 9, 2016 · US 9,254,337Granted
- Activation Of Polysaccharides Via The Cyanylating Agent, 1-CYANOIMIDAZOLE (1-CI), In The Preparation Of Polysaccharide/protein Conjugate VaccinesFeb 2, 2016 · US 9,248,197Granted
- Method for Producing Protein-Carbohydrate Vaccines Reduced in Free CarbohydrateJul 3, 2014 · Application 14167503Pending
- Differential Functionalization of Polymers with Amino-Oxy Reagents for Diagnostic AssaysNov 14, 2013 · Application 13916177Pending
- Antigenic Synthetic Proteins Containing A Tetrazine-amino AcidApplication 19522912Pending
- Chemical Reagents For The Activation Of Polysaccharides In The Preparation Of Conjugate VaccinesApplication PCTUS2022046262Pending
- Production Of Soluble Recombinant ProteinApplication PCTUS2021022126Pending
- Expression And Purification Of CRM197 And Related ProteinsApplication PCTUS2015014130Pending
- Differential Functionalization Of Polymers With Amino-oxy Reagents For Diagnostic AssaysApplication PCTUS2013045413Pending
- Chemical Reagents For The Activation Of Polysaccharides In The Preparation Of Conjugate VaccinesApplication PCTUS2010061133Pending
- Method For Enhancing The Sensitivity Of Antibody Based AssaysApplication PCTUS2010055107Pending
- Method For Producing Protein-carbohydrate Vaccines Reduced In Free CarbohydrateApplication PCTUS2010043387Pending
- Cytoplasmic Expression Of Soluble ProteinsApplication PCTUS2024041710Pending
Recent research by its founders
- Licensed Subcutaneous Infusion Therapies in Advanced Parkinson’s Disease: An Indirect Treatment Comparison and Cost-Minimisation Analysis20257 cites
- Refutation of the <scp>αSyn</scp> ‐ <scp>SAA</scp> ‐Based Staging for Parkinson's Progression (Neuronal α‐Synuclein Disease‐Integrated Staging System <scp>[NSD</scp> ‐ <scp>ISS]</scp> )20257 cites
- Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation20255 cites
Related companies, and why
- Data2Discovery IncSimilar federal contract value in Biotech · $97K in contracts
- FLUENT BIOSCIENCES INCSimilar federal contract value in Biotech · $96K in contracts
- Bellbrook Labs, LLCSimilar federal contract value in Biotech · $90K in contracts
- Celularity IncSimilar federal contract value in Biotech · $80K in contracts
- AUM LIFETECH INCSimilar federal contract value in Biotech · $80K in contracts
- PRIMETIME LIFE SCIENCES, LLCSimilar federal contract value in Biotech · $79K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .